Zheng Quan Shi Bao Wang·2025-11-10 00:39Core Viewpoint - Haina Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] Company Overview - Haina Pharmaceutical is an integrated company providing CXO services for pharmaceutical research and manufacturing, with its own proprietary product pipeline [1] - The company ranks second among CXO service providers in China based on the total number of approved clinical trials and market authorization applications submitted [1] Service Offerings - The company offers a full range of services covering drug discovery, chemistry, manufacturing and controls (CMC), preclinical and clinical development, registration, and validation up to commercial production [1] - As of June 30, 2025, Haina Pharmaceutical has 398 ongoing CXO projects [1] Business Model - The company has proprietary R&D pipelines and chooses to commercialize through drug technology transfer or self-commercialization based on asset characteristics and market considerations [1] - Haina Pharmaceutical has signed 67 drug technology transfer agreements, with representative projects including omeprazole sodium bicarbonate dry suspension [1] Technical Platforms - The company operates eight major technology platforms, including high-end formulation technology, peptide drug formulation, and small molecule innovative drug discovery platforms, covering the entire process from drug chemistry R&D to GMP-scale production [1] - Haina Pharmaceutical has a multidisciplinary pharmaceutical R&D team of 413 professionals focused on drug formulation development and quality control, as well as active pharmaceutical ingredient process development and small molecule innovation research [1]